Agenus’ Surge: How a Strategic Pivot to Early Colon Cancer Treatment Could Redefine Biotech Wins
Agenus shares posted their largest single-day gain after abandoning a Phase 3 colorectal study to focus on early-stage colon cancer. This strategic pivot reduces trial...
